Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Accumulated Expenses for 9 consecutive years, with $18.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 280.16% to $18.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.4 million, a 280.16% increase, with the full-year FY2024 number at $91.1 million, up 1667.68% from a year prior.
  • Accumulated Expenses was $18.4 million for Q3 2025 at Denali Therapeutics, up from $7.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $91.1 million in Q4 2024 to a low of $4.8 million in Q3 2024.
  • A 5-year average of $14.3 million and a median of $8.3 million in 2022 define the central range for Accumulated Expenses.
  • Biggest YoY gain for Accumulated Expenses was 1667.68% in 2024; the steepest drop was 70.45% in 2024.
  • Denali Therapeutics' Accumulated Expenses stood at $19.0 million in 2021, then decreased by 10.13% to $17.1 million in 2022, then crashed by 69.85% to $5.2 million in 2023, then soared by 1667.68% to $91.1 million in 2024, then plummeted by 79.84% to $18.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Accumulated Expenses are $18.4 million (Q3 2025), $7.0 million (Q2 2025), and $7.7 million (Q1 2025).